Again, a Phase 2 trial, recruiting patients with type 2 diabetes, randomised 281 adults to retatrutide, to a comparison drug that is already used in diabetes clinics (dulaglutide, a once-weekly drug that activates only one of retatrutide's three target receptors), or to a dummy injection (placebo) over 36 weeks
For most patients at 0.5 mg who have not achieved treatment goals, the appropriate next step is increasing to 1 mg weekly after at least four weeks at the current dose, provided the medication is well-tolerated
5 5 Strategies There are numerous opportunities in the GLP-1 pharmaceutical landscape, but only for those who can move fast
Try not to weigh yourself every day because this can be discouraging
Use caution in affected patients
Using a degraded or contaminated solution carries real clinical risks, including injection site reactions, systemic infection, or unpredictable pharmacological effects